Peer Review Report For: Zika antiviral chemotherapy: identification of drugs and promising starting points for drug discovery from an FDA-approved library [version 1; peer review: 2 approved]
Rattachement africain : br, fr. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Background The recent epidemics of Zika virus (ZIKV) implicated it as the cause of serious and potentially lethal congenital conditions such microcephaly and other central nervous system defects, as well as the development of the Guillain-Barré syndrome in otherwise healthy patients. Recent findings showed that anti-Dengue antibodies are capable of amplifying ZIKV infection by a mechanism similar to antibody-dependent enhancement, increasing the severity of the disease. This scenario becomes potentially catastrophic when the global burden of Dengue and the advent of the newly approved anti-Dengue vaccines in the near future are taken into account. Thus, antiviral chemotherapy should be pursued as a priority strategy to control the spread of the virus and prevent the complications associated with Zika. Methods Here we describe a fast and reliable cell-based, high-content screening assay for discovery of anti-ZIKV compounds. This methodology has been used to screen the National Institute of Health Clinical Collection compound library, a small collection of FDA-approved drugs. Results and conclusion From 725 FDA-approved compounds triaged, 29 (4%) were found to have anti-Zika virus activity, of which 22 had confirmed (76% of confirmation) by dose-response curves. Five candidates presented selective activity against ZIKV infection and replication in a human cell line. These hits have abroad spectrum of chemotypes and therapeutic uses, offering valuable opportunities for selection of leads for antiviral drug discovery.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Peer Review Report For: Zika antiviral chemotherapy: identification of drugs and promising starting points for drug discovery from an FDA-approved library [version 1; peer review: 2 approved]
- Date Crossref
- 15/11/2016
- Éditeur
- F1000 Research Ltd
- Type
- peer-review
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Instituto Butantan pays non établi dans la noticeStructure de recherche
-
Laboratório Nacional de Ciência e Tecnologia do Bioetanol pays non établi dans la noticeInstitution
-
Brazilian Center for Research in Energy and Materials pays non établi dans la noticeInstitution
-
Brazilian Biosciences National Laboratory pays non établi dans la noticeStructure de recherche
-
BIOASTER pays non établi dans la noticeOrganisation à but non lucratif
-
Fundação Oswaldo Cruz pays non établi dans la noticeStructure de recherche
-
Laboratório Nacional de Biociências pays non établi dans la noticeInstitution
-
Centro de Pesquisas Aggeu Magalhães pays non établi dans la noticeInstitution
Instituto Butantan, Laboratório Nacional de Ciência e Tecnologia do Bioetanol et Brazilian Center for Research in Energy and Materials, avec 5 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.